GEN MED DESTROYING CV!!!

as predicted, the Gen Med Prolia team is bringing in the Repatha numbers while the CV team continues to check how many calls they make and not sell...don't even get me started with the CSO- they bring nothing to the table-Amgen is donating $$ by hiring them. Once again, the Prolia team showing Amgen that we are by far the best sales force in this company!!

 

We at onyx are better than all of you. We will all be gone soon to companies with great cultures and car allowances and no call requirements.

 

the company will give the Prolia team sole ownership of Corlanor and Repatha due to the predicted success with the launch of Repatha(team already outperforming CV) and prior success with Prolia. The CV specialty team will be dissolved based on poor performance- not bringing enough $$- The INBU will get Prolia( romo coming shortly)-SB

 

Yep! CV Specialty Team not aggressive enough! Managers lazy and never in field. Regional Mgr- LOL should I say more.

 

SB -

When is the OBU going to decapitate all Onyx reps, piss on their corpses, then ejaculate on their bloody body pieces?

 

Let me make you understand. If a gen med rep has about 200 for a goal and the CV rep has 350, who has more potential? 350 - 200 = 150 "or less"
for CV rep. I say "or less" because 1 CV territory covers about 1-2 full gen med territories. That means for every .5-1 prescription from CV, the gen med rep should be producing 2-3 prescriptions. That is why the payout is higher on the Gen med side. CV is going to ride your coat tail until Amgen decides to restructure and get rid of extra dead weight! That would include most Inventiv reps and CV reps who can not sell in Cardiology offices!!

To a layoff in 2016. Yay!!

 

Your an idiot! Inventiv reps can outsell the Amgen reps. As to selling in cardiology offices, we all can do that. You sound like a silly, country boy.

 

According to preliminary data the inventiv reps have brought in the least amount of patients to the Repatha hub- by far- on Prolia side there are no positive results with the CSO and Prolia what so ever. " Senior Leadership" already planning to cut the chord with CSO and eliminate at least half of the specialty CV territories nationwide.- SB

 

SB, if that were the case, then why are they hiring the next layer of CSO and management? The positions are posted..

 

they are throwing as many reps out there as they can for a year to "show" the CEO they tried everything in their power to make Repatha a success, than blame the insurance companies for not covering the medicine when the product tanks-massive cuts will come Q4 2016-SB

 

Amgen will merge with another big pharma and you will all be RIFFed

 

Sorry Amgen CV team, very few patients will have access. RIF RIF RIF AWAY!!!

Payers are already looking for ways to forestall spending on new, high-priced PCSK9 drugs--and that could mean good things for AstraZeneca's ($AZN) high-powered statin, Crestor. But it's the soon-to-hit Crestor generics that could prove an even bigger thorn in the sides of PCSK9 drugmakers.

The British pharma's blockbuster is one drug that stands to gain if payers mandate that patients exhaust existing options before graduating to pricey PCSK9s. And while it's all speculation for now, that's a situation that "wouldn't surprise me," AstraZeneca's Marc Ditmarsch, the global development lead for Brilinta, toldFiercePharmaMarketing at the European Society of Cardiology Congress in London.

Right now, list prices for newly approved Praluent from Sanofi ($SNY) and Repatha from Amgen ($AMGN) stand at $14,600 and $14,100, respectively--jumping off points for the payer negotiations that are sure to follow. But according to a report from the Institute for Clinical and Economic Review, the meds' benefits justify prices between $3,615 and $4,811 per year--a 67% discount that payers aren't likely to score.

Express Scripts ($ESRX), for one, is ready to go with its Cholesterol Care Value (CCV) Program, launched before PCSK9s hit the scene. The program uses a "a rigorous clinical documentation process to preserve access to the PCSK9 inhibitors for the right patients," company spokesman David Whitrap toldFiercePharmaMarketing via email, noting that for the "large majority" of high-cholesterol patients, statins are the "clinically appropriate, tried-and-true therapy."

If payer tactics do end up pushing more patients Crestor's way, AstraZeneca certainly wouldn't complain. The company has had some lofty sales goals to meet ever since it set about defending against last spring's Pfizer takeover effort.

But Crestor may not have much time left to rake in diverted PCSK9 sales. The med loses U.S. patent protection in 6 months, and its European shield is set to expire in 17 months. After that, it'll be facing generic competitors--which could appeal to payers even more than Crestor itself, and potentially frustrate Sanofi and Amgen further. Within the statin class, "we will prefer the generics and the lower-priced branded options," Whitrap said of the CCV effort.

Payers aside, there are other reasons docs may not want to prescribe PCSK9s over Crestor and its generics, AZ Brilinta team member David Ginivan toldFiercePharmaMarketing at ESC--and adherence is among them, he noted. Crestor is a pill, which is easier for some patients to keep up with than injections.

There are tradeoffs to getting patients to their cholesterol goals, he said--"whether they stay on their pill, is injection worth the cost--there's a multi-factorial kind of decision-making that has to be there for the physician on that one," he said. "You've got a fantastic drug in Crestor delivering great lipid management, then going generic--that's going to be a challenge for PCSK9 drugs."

 

I knew this would not last.

 

No PCSK9 for you!!!!!

 

BIG PHARMA BIG PHARMA!!!!

FIRE THE REPS

 

My CSO's (all of them) haven't done crap for submissions in the hub. Look at every single doc, they belong to the Prolia reps/docs and very few cards. Keep all the reps who are getting it done and fire the rest.

New people are selling like they are in primary care and assumes paper work will get done when they leave the office. They chase the stupid 9 calls a day and stick to a f'n routing. Route your behind to the offices that have patients and see them often. When you find the patients, sit at your f'n @ss at the offices until you see the fax go through. It is not that difficult.

This is launch mode and not check the box mode! Management needs to wake up and learn to launch too!! Then again, dumb reps need to be told who they should go see and how many times they should be seen.

 

I am banking on this POD monkey model to fail. Looking forward for the layoff announcement!

 

You sir, are a total idiot. You have no idea what you are talking about. Why don't you show us how its done? Bet you can't...

 

My CSO rep still cannot effin get the indication right!!!